Triplebar CEO Maria Cho is scheduled to speak at the 17th annual edition of the Biotech Showcase: The Investor Conference for Innovators that takes place in this Bay Area city from January 8-10.
Biotech Showcase is a top global investor conference designed to provide private and micro-mid-cap biotechnology companies with the opportunity to present to and connect with investors and biopharmaceutical executives. The event attracts investors wielding hundreds of billions of dollars in capital.
Cho will unveil Triplebar鈥檚 recently completed $21M Series A funding round to expand its portfolio in foods and pharmaceuticals, including Antibody Discovery, which leads to enhanced therapeutics solutions with early commercial access.
The prominent Triplebar CEO said she is also excited to be partnered with Howard L. Levine on her Board of Directors, a biologics veteran with over four decades of experience and an industry pioneer and thought leader. He holds a Ph.D. in Chemistry from the University of Chicago and completed a Harvard University post-doctoral fellowship.
More from News
- What Could Snap鈥檚 Partnerships With Big Tech Mean For The AR Industry?
- Why Did A Four-Year Bomb Threat Campaign Involving 500,000 Gmail Accounts Go Unchecked?
- What Do Dario Amodei And The JCHR’s AI Warnings Mean For Startups and SMEs?
- Exabeam Research: Security Leaders Identify AI Agent Access As A Top Insider Risk Priority
- Experts Comment: Is Britain’s Reliance On Foreign Technology Becoming A National Security Risk?
- Full Fibre Adoption Continues To Accelerate Across The UK
- OpenAI, Anthropic And Google Are Discreetly Building Their Own AI Standards Body 鈥� What Would That Actually Decide?
- How Have Digital Nomads Created A New Market For Businesses?
鈥淲e are very pleased to announce Howard as our newest member of the company鈥檚 board. With his expertise, knowledge and vast professional trajectory, the company is even better positioned to make a huge impact in our industry,鈥� Cho said.
Cho will privilege over 3,500 attendees representing over 2,300 firms from 35 countries with a presentation that explains how and why Triplebar is flipping on its head the approach to antibody discovery using her company’s platform to scan antibody libraries of diversity directly for an antibody’s function.
Triplebar has a Hyper-Throughput鈩� screening platform that acts as a 鈥渕icroprocessor for biology,鈥� integrating hardware, software, biology, and biochemistry to miniaturise and accelerate evolution. Triplebar discovers novel therapeutic biologic drug candidates for addressing major human health challenges.
Triplebar鈥檚 microprocessor for biology accesses and assesses 10,000 times more biological samples than any other platform worldwide. Its platform uses the power of evolution at hyperspeed to test and screen tens of millions of molecules and measure the effect of billions of mutations daily, speeding up the discovery of solutions to our carbon crisis and diseases.
